Rheumatoid arthritis

Orthopedic Braces And Supports Market Report 2019: Market is Expected to Reach a Value of USD 8.0 Billion by 2026

Thursday, November 14, 2019 - 10:30pm

Rising prevalence of chronic diseases such as osteoarthritis and rheumatoid arthritis has led to the market growth.

Key Points: 
  • Rising prevalence of chronic diseases such as osteoarthritis and rheumatoid arthritis has led to the market growth.
  • The products restrict mobility to a particular direction, thereby, assisting the overall movement of a patient.
  • Osteoporosis is considered as one of the leading causes of musculoskeletal or joint disorders among geriatric population, leading to the need for orthopedic braces.
  • This factor is anticipated to propel the product demand in orthopedic braces and supports market.

Orthopedic Braces And Supports Market Size, Share & Trends Analysis Report, 2015-2018 & 2019-2026 - ResearchAndMarkets.com

Thursday, November 14, 2019 - 6:19pm

The "Orthopedic Braces And Supports Market Size, Share & Trends Analysis Report By Product (Brace Type, Pain Management Products), By End Use (Orthopedic Clinics, OTC, Hospitals) And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orthopedic Braces And Supports Market Size, Share & Trends Analysis Report By Product (Brace Type, Pain Management Products), By End Use (Orthopedic Clinics, OTC, Hospitals) And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global orthopedic braces and supports market size is expected to reach a value of USD 8.0 billion by 2026.
  • Rising prevalence of chronic diseases such as osteoarthritis and rheumatoid arthritis has led to the market growth.
  • This factor is anticipated to propel the product demand in orthopedic braces and supports market.

SetPoint Medical to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum 2019

Thursday, November 14, 2019 - 2:00pm

Investors attending the conference who would like to schedule a one-on-one meeting with SetPoint management may do so by contacting their Canaccord representative, or Emma Poalillo of The Ruth Group at setpointmedical@theruthgroup.com .

Key Points: 
  • Investors attending the conference who would like to schedule a one-on-one meeting with SetPoint management may do so by contacting their Canaccord representative, or Emma Poalillo of The Ruth Group at setpointmedical@theruthgroup.com .
  • SetPoint Medical is a privately held clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases.
  • SetPoint Medicals bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.
  • The company is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect.

Global Rheumatoid Arthritis Drugs Market Review 2016-2018 & Forecast 2019-2025 - ResearchAndMarkets.com

Wednesday, November 13, 2019 - 11:42am

The report covers a forecast and an analysis of the rheumatoid arthritis drugs market on a global and regional level.

Key Points: 
  • The report covers a forecast and an analysis of the rheumatoid arthritis drugs market on a global and regional level.
  • The study includes drivers and restraints of the rheumatoid arthritis drugs market along with the impact they have on the demand over the forecast period.
  • Additionally, the report includes the study of opportunities available in the rheumatoid arthritis drugs market on a global level.
  • The study provides a decisive view of the rheumatoid arthritis drugs market based on drug type, distribution channel, and region.

eWellness Announces the Developing New Rheumatoid Arthritis Treatment Platform RA360

Tuesday, November 12, 2019 - 2:00pm

Culver City, CA, Nov. 12, 2019 (GLOBE NEWSWIRE) -- eWellness Healthcare Corporation (EWLL) a provider of the state of the art PHZIO platform for the physicaltherapy (PT) and telehealth markets,announced today that it is developing a new Rheumatoid Arthritis Treatment Platform called RA360.

Key Points: 
  • Culver City, CA, Nov. 12, 2019 (GLOBE NEWSWIRE) -- eWellness Healthcare Corporation (EWLL) a provider of the state of the art PHZIO platform for the physicaltherapy (PT) and telehealth markets,announced today that it is developing a new Rheumatoid Arthritis Treatment Platform called RA360.
  • Rheumatoid Arthritis and related autoimmune disorders are the leading cause of illness and disability in the US.
  • Rheumatoid Arthritis (RA): Those with Rheumatoid arthritis will need to go on disability or stop work entirely within 2 years of onset.
  • Our innovative RA360 solution is anticipated to support employees to reduce or maintain their current level of theraputic drug use.

Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting

Tuesday, November 12, 2019 - 11:45am

The study of tofacitinib in JIA is investigative and JIA is not an FDA-approved indication for XELJANZ.

Key Points: 
  • The study of tofacitinib in JIA is investigative and JIA is not an FDA-approved indication for XELJANZ.
  • The JIA study is a Phase 3, randomized, double-blind, placebo-controlled withdrawal study that included 225 patients with polyarticular course JIA (n=184), psoriatic arthritis (n=20) or enthesitis related arthritis (n=21).
  • During the run-in phase, all subjects enrolled in the study received open-label tofacitinib for 18 weeks.
  • It is important to note that a dosage of Xeljanz 10 mg twice daily is not recommended for the treatment of rheumatoid arthritis or psoriatic arthritis.

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis

Saturday, November 9, 2019 - 9:30pm

This study evaluated the ability of the Vectra test to predict patients individual percentage risk of RP within one year.

Key Points: 
  • This study evaluated the ability of the Vectra test to predict patients individual percentage risk of RP within one year.
  • The results demonstrate that the adjusted Vectra score was a superior predictor of RP within one year compared to DAS28-CRP, CRP, CDAI and swollen joint count.
  • Based on these new data, the company is working to enhance the Vectra test report to provide patients with their individual risk of radiographic progression in one year.
  • Vectra is a multi-biomarker molecular blood test that provides an objective and personalized measure of inflammatory disease activity in patients with rheumatoid arthritis.

New data show non-inferiority of efficacy for subcutaneous formulation of CT-P13 (biosimilar infliximab) to intravenous formulation of CT-P13 in people with rheumatoid arthritis

Saturday, November 9, 2019 - 9:30pm

Celltrion Healthcare will target CT-P13 SC as the preferred agent for second-line treatment in rheumatoid arthritis.

Key Points: 
  • Celltrion Healthcare will target CT-P13 SC as the preferred agent for second-line treatment in rheumatoid arthritis.
  • CT-P13 intravenous (IV) formulation is approved in more than 91 countries (as of October 2019) including the US, Canada, Japan and throughout Europe.
  • A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: One Year Results from Part One of a Phase I/III Randomised Controlled Trial in Patients with Rheumatoid Arthritis.
  • A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 30-week Results from Part Two of a Phase I/III Randomised Controlled Trial in Patients with Rheumatoid Arthritis.

SetPoint Medical Announces Oral Presentation of Results from U.S. Pilot Study in Rheumatoid Arthritis Patients at American College of Rheumatology (ACR) Annual Meeting 2019

Tuesday, October 29, 2019 - 1:00pm

VALENCIA, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that results from its U.S. pilot Investigational Device Exemption (IDE) study in rheumatoid arthritis (RA) have been accepted for oral presentation at the American College of Rheumatology (ACR) Annual Meeting, being held November 8-13, 2019 in Atlanta, GA.

Key Points: 
  • VALENCIA, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that results from its U.S. pilot Investigational Device Exemption (IDE) study in rheumatoid arthritis (RA) have been accepted for oral presentation at the American College of Rheumatology (ACR) Annual Meeting, being held November 8-13, 2019 in Atlanta, GA.
  • The multicenter, double-blind, randomized controlled U.S. pilot study evaluated the safety and tolerability of SetPoints proprietary wireless microregulator device for the treatment of drug-refractory RA patients.
  • SetPoint completed enrollment in October 2018 and will present results for the primary endpoint at 12 weeks.
  • The company is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect.

Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis

Tuesday, October 29, 2019 - 11:30am

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from the Companys first interim analysis of its ongoing NAV3-31 Phase 2B study.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from the Companys first interim analysis of its ongoing NAV3-31 Phase 2B study.
  • Dr. Rosol continued, With these exciting results in hand, we continue to enroll subjects as planned to complete this Phase 2B and prepare for the upcoming Phase 3.
  • Jed Latkin, Navideas Chief Executive Officer, said, I am very pleased that the results of this interim analysis are so encouraging.
  • It reaffirms that we are heading in the right direction with our clinical trial pipeline in rheumatoid arthritis.